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ing an erythropoiesis-stimulating therapy (EST). Patients were
included in this analysis if they were >=65 years old and received
therapy between October 2005 and October 2006. Patient
demographics, comorbid conditions, baseline hemoglobin, CKD
status, EST dose, and frequency of administration were collected.
Drug cost was based on average weekly dose and September
2006 wholesale acquisition cost (EPO $12.17/1000 Units; DARB
$4.446/mcg). RESULTS: 862 patient charts were reviewed; 556
patients met eligibility criteria (EPO: 351; DARB: 205). Patient
demographics, comorbid conditions, baseline hemoglobin, and
CKD status were similar between groups. Weekly and extended
(>= every two weeks [>= Q2W]) dosing patterns were seen in
both groups (EPO: QW, 39%; >= Q2W, 61%; DARB: QW, 8%;
>= Q2W, 92%). The average weekly dose over the course of the
study (EPO: 10,719 units; DARB: 48 mcg) corresponded to a
dose ratio of 223 : 1 (Units EPO: mcg DARB) and weekly costs
of $130 for EPO and $213 for DARB. CONCLUSION: The
doses and 39% lower drug cost in the EPO group observed in
this study were similar to those published from earlier time
periods. The results reported here should be of assistance to clin-
icians and formulary decision makers in identifying current real-
world dosing and subsequent cost of treatment of these two
erythropoietic agents.
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OBJECTIVES: To study treatment outcomes (total cost, hospi-
talization, hospital stays and physician ofﬁce visits) associated
with thiazolidinedione (TZD) use among Medicare patients with
type II diabetes. METHODS: Medicare Current Beneﬁciary
Survey Cost and Use ﬁles 2000 and 2001 were used. Patient-year
approach was utilized. After applying inclusion and exclusion
criteria, patients’ sociodemographic and clinical characteristics
were characterized and compared across different treatment
groups. Instrumental variable (IV) methodology was applied
with TZD geographic area use rate as instrument and IV assump-
tions were validated. The results of IV method were compared
to that of standard ordinary least square (OLS) approach.
RESULTS: A total of 417 patients were included in the ﬁnal
analysis. More patients with actual TZD treatment had comor-
bidities >0 (69.8% vs. 56.4%, p < 0.05) and less were non-
white/black race (1% vs 7%, p < 0.05) than those without. The
TZD use rates were 17% and 29% for lower (<20%) and higher
TZD area use rate groups respectively (p < 0.01). Unadjusted
OLS models showed that actual TZD use was associated with
increased total annual cost (co-efﬁcient = 0.38, p < 0.01) and risk
of having more physician ofﬁce visits by 81%. Adjusted OLS
models showed that actual TZD use was still associated with
increased total annual cost (co-efﬁcient = 0.23, p < 0.05) and risk
of having more physician ofﬁce visits by 64% (p < 0.05). IV
approach demonstrated that higher TZD area use rate was not
associated with total annual cost, hospitalization and hospital
stays (p > 0.1). IV assumption for physician ofﬁce visits was vio-
lated as indicated by a signiﬁcant Wu-Hausman test. CON-
CLUSION: Increasing average TZD area treatment rate from
17% to 29% would not lead to increased total annual cost, hos-
pitalization and hospital stays among marginal patients in the
cohort of senior diabetic patients in this study. Future research
utilizing data with large sample size is suggested.
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OBJECTIVES: Both cost and quality are major concerns in the
U.S. health care system. The objective of this study is to identify
the relationship between cost and quality from the health care
consumers’ perspective. METHODS: Using the 2003 Medical
Expenditure Panel Survey (MEPS), a nationally representative
sample of 13,980 adults (age ≥ 18) with their overall self-rating
of health care quality (from 0 (worst health care possible) to 
10 (best health care possible)) were included in the study. Given
the heavily right-skewed distribution of the cost data, a general-
ized linear model with log-link function was employed to iden-
tify the relationship between health care quality rating and 
total health care expenditure, after controlling for individual
demographic covariates, comorbidity proﬁle (AHRQ comorbid-
ity software), and functional and activity limitations. All sta-
tistics were adjusted using the proper sampling weight from 
the MEPS. RESULTS: The average annual health care expendi-
tures ranged between $4000 and $6000 with the mean value
$4779 for all individuals rating their received health care quality
from 0 to 10. Individuals with higher ratings for their health 
care quality did not spend more compared to individuals with
lower ratings (p = 0.72). No non-monotonic relationship 
was identiﬁed either. As one expected, comorbidities and func-
tional and activity limitations were signiﬁcant predictors of the
annual health care expenditure. An individual-level ﬁxed-effect
model using the 2003–2004 panel of the MEPS revealed the same
relationship between health care quality rating and total health
care expenditure. CONCLUSION: This study adds to the liter-
ature of health care quality by providing additional empirical evi-
dence from the health care consumers’ perspective at the U.S.
national level. Health care quality improvement, in regards to
patient satisfaction, may not require additional health care
spending.
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OBJECTIVES: This study presents a methodology to estimate
type II diabetes prevalence, treatment and costs among the ∼178
million individuals in the U.S. with employer-sponsored insur-
ance (ESI). METHODS: Estimates were made from the 2005
MarketScan® Commercial and Medicare supplemental data-
bases, which include all health care claims for approximately 
20 million employees, dependents, and retirees with ESI. The
Sample Select Prevalence tool was used to identify patients with
Type II diabetes (ICD-9-CM = 250.x0 or 250.x2) and drug treat-
ment (insulin, sulfonylurea, or other oral antidiabetic drug),
summarize annual health care expenditures, and calculate preva-
lence rates. To project these rates to the national ESI population,
weights were developed using the Household Component of the
Medical Expenditure Panel Survey (MEPS). To construct the
weights, MEPS respondents were stratiﬁed using combinations
of demographic characteristics which account for substantial dif-
ferences in utilization and expenditures. RESULTS: In the 2005
MarketScan databases, 835,048 patients with diabetes (5320
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diabetes/100,000) were identiﬁed, projecting to a national ESI
rate of 4814/100,000. Over half of all diabetics had drug treat-
ment; 854.6/100,000 with insulin, 1,536.1/100,000 with sul-
fonylurea, and 2,427.6/100,000 with other treatments, including
metformins, TZDs, and combination products. Annual health
care expenditures for diabetics, with or without drug treatment,
was $14,138. Annual expenditures were $23,223, $14,045, and
$13,252, for patients treated with insulins, sulfonulureas, and
other treatments, respectively. CONCLUSION: Reliable esti-
mates of the prevalence, treatment and cost of diabetes and other
conditions, are valuable to policy makers, providers, and payers.
Individuals with ESI represent over 56% of the U.S. population,
a large group with fewer cost barriers to care. This study demon-
strates a reliable projection methodology for estimating disease
prevalence, treatment events, and costs associated with any
disease or condition based on a large convenience sample of
health care claims data.
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OBJECTIVES: To evaluate the impact of identifying and inter-
vening upon inefﬁcient dosing practices related to atypical
antipsychotics in a large commercial managed care organization.
METHODS: An analysis using the Interactive Prescribing Efﬁ-
ciency Tool (iPET) was conducted to identify inefﬁcient pre-
scribing among atypical antipsychotics. Pill combinations used
to reach all daily doses for the atypicals were identiﬁed and base-
line opportunity cost savings calculated. A pharmacy claims edit
was instituted for all atypicals on July 1, 2004. Prescriptions
were ﬂagged at the pharmacy level if inefﬁcient dosing was
present and automatic optimization of regimens was imple-
mented based on predetermined algorithms. The iPET was used
to reevaluate the success of this intervention at improving eco-
nomic outcomes. RESULTS: We identiﬁed 1215 patients receiv-
ing an atypical antipsychotic during the pre-intervention period
(aripiprazole n = 153; olanzapine n = 284; quetiapine n = 469;
risperidone n = 289; ziprasidone n = 81). Some patients may have
received multiple atypicals. Inefﬁcient pill combinations may
have been received by 7.8%, 18.7%, 27.9%, 27.7%, and 23.5%
of aripiprazole, olanzapine, quetiapine, risperidone, and ziprasi-
done patients, respectively. An opportunity savings of $157,401
in overall atypical antipsychotic expenditures was estimated (if
up to 70% of inefﬁcient doses were converted to more efﬁcient
pill combinations). In the period after the dose optimization
program had been implemented, we identiﬁed 1166 patients as
receiving an atypical (aripiprazole n = 158; olanzapine n = 258;
quetiapine n = 463, risperidone n = 250; ziprasidone n = 80).
During this period, inefﬁcient pill combinations may have 
been received by 4.4%, 8.5%, 38.9%, 10.0%, and 20% of aripi-
prazole, olanzapine, quetiapine, risperidone, and ziprasidone
patients, respectively. The opportunity savings dropped to
$58,385 indicating a costs savings of $99,016 following the
implementation of the dose optimization intervention. CON-
CLUSIONS: Substantial improvements in economic outcomes
were realized through an intervention focused on increasing pre-
scribing efﬁciency among the atypical antipsychotics.
MH2
COMPARISON OF HEALTH CARE COSTS AND
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OBJECTIVES: To compare the health care costs and hospital-
ization days of elderly major depressive disorder (MDD) patients
treated with escitalopram to those treated with other SSRI/SNRI.
METHODS: Elderly MDD patients (age °Y´65) initiated on esc-
italopram or other SSRI/SNRI were identiﬁed in the IHCIS
National Managed Care Database (2003 ¨C 2005). Health care
costs and hospitalization days were compared between patients
on escitalopram to those on other SSRI/SNRI over 6 months fol-
lowing therapy initiation (study period). Wilcoxon tests were
used to compare the costs descriptively. Diff-in-diff analyses were
conducted to control for baseline (the 6 months prior to therapy
initiation) costs. GLM regression with log link function was used
for total health care cost comparison. Negative binomial regres-
sion was used to compare the number of hospitalization days.
Both regressions adjusted for patient demographics, comorbidi-
ties, and medical resource use at baseline. Costs were inﬂation
adjusted to 2005 US dollars. RESULTS: The study sample
included 459 elderly MDD patients initiated on escitalopram and
1517 patients initiated on other SSRI/SNRI. Descriptive analy-
ses showed that patients on escitalopram had $2143 lower six-
month total health care costs than patients on other SSRI/SNRI
(p = 0.398), and about half of the difference was from lower hos-
pitalization costs ($1271, p = 0.145). After adjusting for base-
line costs using the diff-in-diff method, the difference in total
health care costs became signiﬁcant ($2319, p = 0.037), and
about one third of the difference was from lower hospitalization
costs ($806, p = 0.036). The GLM regression showed that the
six-month total health care costs of patients on escitalopram 
was $3120 less than patients on other SSRI/SNRI (p = 0.001). 
Negative binomial regression showed that patients on escitalo-
pram had 39% less hospitalization days (p = 0.004). CON-
CLUSION: Compared to elderly MDD patients initiated on
other SSRI/SNRI, patients who initiated escitalopram have lower
health care costs and less hospitalization.
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OBJECTIVES: Patients with schizophrenia commonly suffer
from clinically relevant co-morbidities, including alcoholism,
substance abuse, and hepatitis, that may compromise hepatic
function. The study was designed to evaluate the prevalence of
liver diseases in patients with schizophrenia as compared to non-
mentally ill controls. METHODS: South Carolina State Medic-
aid program data were analyzed. Patients <65 years, with a
schizophrenia diagnosis (ICD-9CM) from January 2002 to
December 2003 were identiﬁed. A 4 : 1 random selection algo-
rithm (4 without diagnosis to 1 with diagnosis) was applied.
Prevalence of liver diseases was assessed from ambulatory or
hospital claims over the 24-month period (January 2004–
December 2005) and compared between the two groups. The
liver disease related ICD-9CM codes included 570–573.xx,
070.xx, 782.4, 790.4, 794.8 for acute liver disease, alcoholic
